Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
04
02
2020
revised:
25
08
2020
accepted:
17
09
2020
pubmed:
4
10
2020
medline:
7
10
2021
entrez:
3
10
2020
Statut:
ppublish
Résumé
The pharmacological and adverse effect profiles of the two approved therapies for IPF make the development of new therapies challenging. Considering the similarity of the characteristics of drug candidates to Standard of Care is important in defining positioning and development strategies for this disease.
Identifiants
pubmed: 33010480
pii: S1359-6446(20)30376-7
doi: 10.1016/j.drudis.2020.09.019
pii:
doi:
Substances chimiques
Drug Combinations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2277-2283Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.